Monday, March 30, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Understanding of Clinical Evidence in Peptide and Hormone Use

Instructions:
Please indicate your level of agreement with each statement using the following scale:
Strongly Disagree | Disagree | Neutral | Agree | Strongly Agree

I am familiar with how clinical studies are typically structured (e.g., randomized, observational, controlled).
I can distinguish between early-stage studies and large, late-stage clinical trials. 
I can distinguish between early-stage studies and large, late-stage clinical trials. 
I feel confident interpreting the primary outcomes reported in clinical studies. 
I feel confident interpreting the primary outcomes reported in clinical studies. 
I recognize that statistical significance does not always imply clinical relevance. 
I recognize that statistical significance does not always imply clinical relevance. 
I take into account potential sources of bias when reviewing clinical research. 
I take into account potential sources of bias when reviewing clinical research. 
I consider whether findings have been replicated in multiple studies.
I consider whether findings have been replicated in multiple studies.
I consider whether clinical evidence directly applies to the specific peptide or hormone I am using
I consider whether clinical evidence directly applies to the specific peptide or hormone I am using
I recognize that outcomes observed in one context may not apply in another. 
I recognize that outcomes observed in one context may not apply in another. 
I rely on multiple sources when learning about peptides and hormones.
I rely on multiple sources when learning about peptides and hormones.
I distinguish between clinical research and promotional or non-clinical content. 
I distinguish between clinical research and promotional or non-clinical content. 
I am comfortable making decisions when clinical evidence is incomplete. 
I am comfortable making decisions when clinical evidence is incomplete. 
I recognize that uncertainty is a common feature of emerging therapies.
I recognize that uncertainty is a common feature of emerging therapies.
I feel confident in my ability to interpret clinical research related to peptides and hormones. 
I feel confident in my ability to interpret clinical research related to peptides and hormones. 
I recognize areas where my understanding of the evidence may be limited.
I recognize areas where my understanding of the evidence may be limited.
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!